FDA-cleared profile

Sonio Detect

Sonio · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Concurrent aid during acquisition and interpretation of fetal ultrasound examinations across gestational ages 11-37 weeks to detect supported views and structures and verify view quality criteria and characteristics.

Clinical role
Real-time concurrent acquisition and interpretation aid for exam completeness and protocol checking; the healthcare professional can reassign or unassign views and override quality or characteristic outputs.
Images and patients
Ultrasound · Fetus/obstetric anatomy, including fetal brain, heart/thorax, abdomen, placenta, and genitalia
Key limitation
Keep in mind: The packet states that Sonio Detect was validated only with GE, Canon, Philips, and Samsung ultrasound devices and is intended only for those vendors. Outputs are concurrent reading aids that can be overridden by the user; the packet does not establish a diagnostic conclusion or a clinical-outcome claim. No clinical study was required for substantial equivalence.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Concurrent aid during acquisition and interpretation of fetal ultrasound examinations across gestational ages 11-37 weeks to detect supported views and structures and verify view quality criteria and characteristics.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Fetus/obstetric anatomy, including fetal brain, heart/thorax, abdomen, placenta, and genitalia Input: Fetal ultrasound images and clips from GE Medical, Samsung, Canon, or Philips ultrasound machines, covering trimester 1, 2, or 3 and gestational age 11-37 weeks; DICOM instances are received by edge software on a server connected to the ultrasound-machine network.
  • Who uses it?Intended users: Sonographers, OB/GYN maternal-fetal medicine specialists, and fetal surgeons as healthcare professionals
  • What does the software produce?Output: Automatic detection of 7 first-trimester or 18 second/third-trimester views, supported fetal anatomical structures, presence or absence quality criteria, placenta location (anterior/posterior), and fetal sex (male/female), with yellow highlighting for unverified items and user-editable assignments.
  • What is its most important limitation?Key limitation: The packet states that Sonio Detect was validated only with GE, Canon, Philips, and Samsung ultrasound devices and is intended only for those vendors. Outputs are concurrent reading aids that can be overridden by the user; the packet does not establish a diagnostic conclusion or a clinical-outcome claim. No clinical study was required for substantial equivalence.

Clinical takeaway. Clinical role: Concurrent aid during acquisition and interpretation of fetal ultrasound examinations across gestational ages 11-37 weeks to detect supported views and structures and verify view quality criteria and characteristics.

Evidence takeaway. Evidence from the reviewed source record: FDA K240406 reports standalone performance testing on 36,769 fetal ultrasound images using a global validation dataset independent of development and operating-point data. The table reports endpoint-specific sensitivity and specificity: view sensitivity was 0.914 for 7 first-trimester views and 0.937 for 18 second/third-trimester views; paired structure or characteristic results included brain 0.934/0.949, thorax and heart 0.861/0.938 for trimester 1 and 0.919/0.976 for trimesters 2/3, placenta structures 0.967/0.856, CRL/NT/profile 0.898/0.862 for trimester 1 and 0.893/0.956 for trimesters 2/3, anterior placenta location 0.959/0.966, posterior location 0.966/0.959, female sex 0.977/0.987, and male sex 0.987/0.977. The table also reports sensitivity-only values of 0.892 for 3D-image detection, 0.973 for Doppler-image detection, and 0.913 for view detection from image annotations.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Concurrent aid during acquisition and interpretation of fetal ultrasound examinations across gestational ages 11-37 weeks to detect supported views and structures and verify view quality criteria and characteristics.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Real-time concurrent acquisition and interpretation aid for exam completeness and protocol checking; the healthcare professional can reassign or unassign views and override quality or characteristic outputs.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Fetal ultrasound images and clips from GE Medical, Samsung, Canon, or Philips ultrasound machines, covering trimester 1, 2, or 3 and gestational age 11-37 weeks; DICOM instances are received by edge software on a server connected to the ultrasound-machine network.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Automatic detection of 7 first-trimester or 18 second/third-trimester views, supported fetal anatomical structures, presence or absence quality criteria, placenta location (anterior/posterior), and fetal sex (male/female), with yellow highlighting for unverified items and user-editable assignments.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Clinical fetal ultrasound acquisition and interpretation workflow
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Sonographers, OB/GYN maternal-fetal medicine specialists, and fetal surgeons as healthcare professionals
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
The packet states that Sonio Detect was validated only with GE, Canon, Philips, and Samsung ultrasound devices and is intended only for those vendors. Outputs are concurrent reading aids that can be overridden by the user; the packet does not establish a diagnostic conclusion or a clinical-outcome claim. No clinical study was required for substantial equivalence.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA K240406 reports standalone performance testing on 36,769 fetal ultrasound images using a global validation dataset independent of development and operating-point data. The table reports endpoint-specific sensitivity and specificity: view sensitivity was 0.914 for 7 first-trimester views and 0.937 for 18 second/third-trimester views; paired structure or characteristic results included brain 0.934/0.949, thorax and heart 0.861/0.938 for trimester 1 and 0.919/0.976 for trimesters 2/3, placenta structures 0.967/0.856, CRL/NT/profile 0.898/0.862 for trimester 1 and 0.893/0.956 for trimesters 2/3, anterior placenta location 0.959/0.966, posterior location 0.966/0.959, female sex 0.977/0.987, and male sex 0.987/0.977. The table also reports sensitivity-only values of 0.892 for 3D-image detection, 0.973 for Doppler-image detection, and 0.913 for view detection from image annotations.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K240406 reports standalone performance testing on 36,769 fetal ultrasound images using a global validation dataset independent of development and operating-point data. The table reports endpoint-specific sensitivity and specificity: view sensitivity was 0.914 for 7 first-trimester views and 0.937 for 18 second/third-trimester views; paired structure or characteristic results included brain 0.934/0.949, thorax and heart 0.861/0.938 for trimester 1 and 0.919/0.976 for trimesters 2/3, placenta structures 0.967/0.856, CRL/NT/profile 0.898/0.862 for trimester 1 and 0.893/0.956 for trimesters 2/3, anterior placenta location 0.959/0.966, posterior location 0.966/0.959, female sex 0.977/0.987, and male sex 0.987/0.977. The table also reports sensitivity-only values of 0.892 for 3D-image detection, 0.973 for Doppler-image detection, and 0.913 for view detection from image annotations.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Endpoint-specific, not device-level: fetal brain 93.4%; fetal thorax/heart 86.1% at T1 and 91.9% at T2/T3; additional view and characteristic rows are reported in the FDA table.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08

FDA K240406 reports separate trimester-, view-, structure-, and characteristic-specific endpoints; the prior 95%/95% pair was not an observed overall result.

Reported specificity
Endpoint-specific, not device-level: fetal brain 94.9%; fetal thorax/heart 93.8% at T1 and 97.6% at T2/T3; specificity is not reported for some image-type endpoints.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08

FDA K240406 reports separate trimester-, view-, structure-, and characteristic-specific endpoints; the prior 95%/95% pair was not an observed overall result.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Sonio Detect regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K240406
  • Samplen=36769
  • IndependenceIndependence not established

K240406

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240406. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Fetal ultrasound images and clips from GE Medical, Samsung, Canon, or Philips ultrasound machines, covering trimester 1, 2, or 3 and gestational age 11-37 weeks; DICOM instances are received by edge software on a server connected to the ultrasound-machine network.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K240406: Sonio Detect

  2. Routing

    Source context, not route validation: The packet describes edge software on a local server receiving DICOM instances from the ultrasound machine, uploading them to Sonio Cloud, and SaaS access through an internet browser, with Chrome recommended. It does not establish a specific PACS, RIS, EHR, interface version, or pure cloud-only deployment.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K240406: Sonio Detect

  3. AI processing

    Source context, not route validation: The exact FDA package describes Sonio Detect as a Software as a Service solution accessible from an internet browser, with Edge Software installed on the HCP server and network to receive DICOM instances from the ultrasound machine and upload them to Sonio's Cloud. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Sonio Detect is a Software as a Service SaaS solution that aims at helping sonographers," … "SaaS accessibility from any internet browser (recommended browser: Google Chrome).". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K240406: Sonio Detect

  4. Returned objects

    Source context, not route validation: Automatic detection of 7 first-trimester or 18 second/third-trimester views, supported fetal anatomical structures, presence or absence quality criteria, placenta location (anterior/posterior), and fetal sex (male/female), with yellow highlighting for unverified items and user-editable assignments.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K240406: Sonio Detect

  5. Viewer/worklist/report

    Unresolved route: Automatic detection of 7 first-trimester or 18 second/third-trimester views, supported fetal anatomical structures, presence or absence quality criteria, placenta location (anterior/posterior), and fetal sex (male/female), with yellow highlighting for unverified items and user-editable assignments.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K240406: Sonio Detect

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Sonio Detect as a Software as a Service solution accessible from an internet browser, with Edge Software installed on the HCP server and network to receive DICOM instances from the ultrasound machine and upload them to Sonio's Cloud. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Sonio Detect is a Software as a Service SaaS solution that aims at helping sonographers," … "SaaS accessibility from any internet browser (recommended browser: Google Chrome).". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The packet describes edge software on a local server receiving DICOM instances from the ultrasound machine, uploading them to Sonio Cloud, and SaaS access through an internet browser, with Chrome recommended. It does not establish a specific PACS, RIS, EHR, interface version, or pure cloud-only deployment.
  • Exact FDA submission
  • Checked 2026-09-08
Security
Sonio's security page states HIPAA and GDPR compliance, HDS-certified cloud providers, SOC 2 Type 2 compliance, encryption at rest and in transit, a web application firewall with intrusion detection, and isolated regional deployments. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Sonio Detect; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240406
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Fetus/obstetric anatomy, including fetal brain, heart/thorax, abdomen, placenta, and genitalia
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-04-26
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K240406 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K240406: Sonio Detect

    U.S. Food and Drug Administration - Published 2024-04-26 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Sonio Detect model card (K240406)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K240406

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. Sonio Security and Medical Device Regulatory Info

    Sonio - Accessed 2026-10-25

    Scope: security

Research history

  1. K240406 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251368

FETOLY

Diagnoly

Authorized purpose: FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.

Modality
Ultrasound
Anatomy
Fetal heart and fetal brain
Decision
2025-09-12
FDA-cleared K251071

Fetal EchoScan (v1.1)

BrightHeart

Authorized purpose: Adjunctive detection of suspicious fetal cardiac findings during second-trimester ultrasound to aid concurrent OB-GYN or maternal-fetal-medicine interpretation.

Modality
Ultrasound
Anatomy
Fetal heart, including four-chamber, left-ventricular-outflow-tract, and right-ventricular-outflow-tract views and the specified suspicious cardiac findings
Decision
2025-05-02

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history